论文部分内容阅读
目的 研究原发性肺癌组织端粒酶活性检测的临床应用价值 ,探讨其作为肺癌诊断和预后评价指标的可行性。方法 采用端粒重复序列扩增 -酶联免疫吸附法 (TRAP -ELISA法 ) ,对 32例原发性肺癌手术切除组织及相应的癌旁组织进行端粒酶活性分析 ,并以 7例肺良性病变作为对照。结果 32例肺癌组织端粒酶水平明显高于癌旁组织 (P <0 .0 5 )及良性病变组织(P <0 .0 0 1)。肺癌组织中端粒酶阳性率为 84 .4 % ,癌旁组织为 9.4 % ,在良性组织中未检出端粒酶阳性。端粒酶活性随临床分期有升高趋势 ,伴淋巴结转移标本组中其阳性率明显高于非淋巴结转移组 (P <0 .0 5 ) ,但与肿瘤病理组织学类型、分化程度等未显示有统计学差异。结论 端粒酶激活与肺癌的发生、发展密切相关。端粒酶可以成为一种用于肺癌辅助诊断、预后判断的重要标志物并在肺癌的基因治疗中发挥作用。
Objective To study the clinical value of detecting telomerase activity in primary lung cancer and to explore its feasibility as a diagnostic and prognostic indicator of lung cancer. Methods The telomerase activity was analyzed in 32 cases of primary lung cancer resected tissues and corresponding para-cancerous tissues by telomeric repeat amplification-enzyme-linked immunosorbent assay (TRAP-ELISA), and 7 cases of benign lung Lesions served as controls. Results The level of telomerase in 32 lung cancer tissues was significantly higher than that in adjacent non-cancerous tissues (P <0.05) and benign lesions (P <0.01). The positive rate of telomerase in lung cancer tissues was 84.4% and that in paracancerous tissues was 9.4%. No telomerase positive was detected in benign tissues. The telomerase activity increased with the clinical stage, and the positive rate in the group with lymph node metastasis was significantly higher than that in the non-lymph node metastasis group (P <0.05), but not with the histopathological types and differentiation degree There are statistical differences. Conclusion The activation of telomerase is closely related to the occurrence and development of lung cancer. Telomerase can become an important marker for diagnosis and prognosis of lung cancer and play a role in the gene therapy of lung cancer.